FLURBIPROFEN LOADED TRANSFEROSOME DEVELOPMENT AND EVALUATION TO IMPROVE TRANSDERMAL DELIVERY
Abstract
Numerous joint tissues may be impacted by osteoarthritis, a degenerative joint condition. With over 32.5 million persons affected, it is the most prevalent kind of arthritis. Benefits and drawbacks of traditional drug delivery systems include low solubility and permeability, poor bioavailability, breakdown by GI enzymes, first pass metabolism, need for high doses, and associated drug toxicity. Therefore, the goal of this research is to create a transferosomal gel containing flurbiprofen to treat arthritis. The standard protocol was followed in the formulation and assessment of the prepared gel. According to the results, the F-12 formulation has the highest entrapment effectiveness (73.49%) and the smallest vesicle size (165.58%). The zeta potential of F12 was discovered to be -38.85. Additionally, the optimised gel OTGF1 demonstrated an Extrudability (g) of 185±2.5 g and a Spreadability (g.cm/sec) of 11.15±1.5 g.cm/sec, respectively, according to transferosomal gel evaluation. The measured viscosity of the gel was 32151±8 cps. The estimated percentage of transferosomal gel assay was 98.15±0.32%. The percentage of cumulative drug release at 12 hours was determined to be 92.23. Following the Higuchi model, the r 2 value from the release Kinetics of the optimised gel of transferosomal gel was found to be 0.990. Therefore, it may be said that Transfersomal gel was invented for financial gain in order to increase the stability of drug-carrying vesicles and facilitate topical application.
Keywords: Novel drug delivery system, Osteoarthritis, Rheumatoid arthritis. Transferososme, Flurbiprofen, Transferosomal gel
References
Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Medical Clinics. 2020 Mar 1;104(2):293-311.
Goldring MB, Otero M. Inflammation in osteoarthritis. Current opinion in rheumatology. 2011 Sep;23(5):471.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases. 2014 Jul 1;73(7):1316-22.
Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2019 Mar 1;27(6):501-7.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011 Dec 8;365(23):2205-19.
Bader RA. The development of targeted drug delivery systems for rheumatoid arthritis treatment. Rheumatoid Arthritis–Treatment. Rijeka and Shanghai: InTech. 2012 Jan 18;18:111-32.
Tarner IH, Müller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Expert opinion on drug delivery. 2008 Sep 1;5(9):1027-37.
Deshmukh R. Rheumatoid arthritis: pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system. Materials Today Communications. 2023 Mar 23:105877.
Benson HA. Transfersomes for transdermal drug delivery. Expert opinion on drug delivery. 2006 Nov 1;3(6):727-37.
Malakar J, Sen SO, Nayak AK, Sen KK. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi pharmaceutical journal. 2012 Oct 1;20(4):355-63.
Ghanbarzadeh S, Arami S. Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. BioMed research international. 2013 Oct;2013.
Qushawy M, Nasr A, Abd-Alhaseeb M, Swidan S. Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics. 2018 Feb 23;10(1):26.
Sharma A, Dubey A, Gupta P, Yadav R, Saraogi R. Transferosome: novel drug delivery system. International Journal of Biological & Pharmaceutical Research. 2012;3(5):722-8.
Jivrani SD, Patel VK. formulation, development and evaluation of niosomal drug delivery system for clindamycin phosphate. Pharma Science Monitor. 2014 Apr 2;5.
